Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schieppati, A.
Right arrow Articles by Remuzzi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schieppati, A.
Right arrow Articles by Remuzzi, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2003) 18: 858-859
© 2003 European Renal Association-European Dialysis and Transplant Association

Editorial Comment

Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries

Arrigo Schieppati1,2, Norberto Perico1 and Giuseppe Remuzzi1,2,

1 Mario Negri Institute for Pharmacological Research, Negri Bergamo Laboratories, Bergamo and 2 Ospedali Riuniti di Bergamo, Division of Nephrology and Dialysis, Bergamo, Italy

Keywords: developing countries; end-stage renal disease; renal replacement therapy; screening

The first 10% of the full text of this article appears below.

There are about 1 million people in the world that are alive just because they have access to one form or another of renal replacement therapy (RRT) [1]. Ninety percent of them live in the developed countries, or, as they are defined by the World Bank (WB), high-income countries, where the average gross income is in excess of $10 000 per capita.

There is a clear, direct relationship between gross national product (GNP) and availability of RRT. Dialysis treatment absorbs 0.7 to 1.8% of the health care budget in European countries, while the dialysis population represents 0.02 to 0.05% of the whole population [2]. In the Eastern European countries, the so-called former Soviet block, the prevalence rate of RRT is half . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CJASNHome page
P. Ruggenenti, P. Bettinaglio, F. Pinares, and G. Remuzzi
Angiotensin Converting Enzyme Insertion/Deletion Polymorphism and Renoprotection in Diabetic and Nondiabetic Nephropathies
Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1511 - 1525.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
I. Codreanu, N. Perico, and G. Remuzzi
Dual Blockade of the Renin-Angiotensin System: The Ultimate Treatment for Renal Protection?
J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S34 - S38.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
C. Chiurchiu, G. Remuzzi, and P. Ruggenenti
Angiotensin-Converting Enzyme Inhibition and Renal Protection in Nondiabetic Patients: The Data of the Meta-Analyses
J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S58 - S63.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A. Benigni, D. Corna, C. Zoja, L. Longaretti, E. Gagliardini, N. Perico, T. M. Coffman, and G. Remuzzi
Targeted Deletion of Angiotensin II Type 1A Receptor Does not Protect Mice from Progressive Nephropathy of Overload Proteinuria
J. Am. Soc. Nephrol., October 1, 2004; 15(10): 2666 - 2674.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
P. L. SantaCruz
Preventing end-stage kidney disease: a personal opinion from the Third World
Nephrol. Dial. Transplant., November 1, 2003; 18(11): 2453 - 2453.
[Full Text] [PDF]